There are many exciting advances happening in the field of mantle cell lymphoma.
It is an exciting time for mantle cell lymphoma (MCL), with new treatments being explored that will lead to better patient outcomes, according to Michael Wang, M.D., professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center.
Progress is being made in targeted therapies, immunotherapy and cell therapies, according to Wang, who said that in his lifetime, there might be a percentage of patients who are cured of the disease.
